Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm

NCT03119701 is registered in ClinicalTrials.gov with Faron Pharmaceuticals Ltd as lead sponsor.

NCT NCT03119701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03119701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm
Lead sponsor
Faron Pharmaceuticals Ltd
Phase
Phase 2
Overall status
Terminated
Start date
February 18, 2017
Completion date
October 3, 2019
Enrollment
40 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

multi organ failure, preventive medicine